Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update-Reference-Cited by-同舟云学术

Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update

Published:2016-08-08 Issue: Volume:5 Page:1933
ISSN:2046-1402
Container-title:F1000Research
language:en
Short-container-title:F1000Res

Author:

Hong Jung Yong,Suh Cheolwon,Kim Won Seog

Abstract

Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL.

Publisher

F1000 Research Ltd

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://f1000research.com/articles/5-1933/v1/pdf

Reference53 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.;B Coiffier;N Engl J Med.,2002

2. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.;M Pfreundschuh;Lancet Oncol.,2006

3. Relapsed/refractory diffuse large B-cell lymphoma.;J Friedberg;Hematology Am Soc Hematol Educ Program.,2011

4. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.;C Récher;Lancet.,2011

5. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.;W Wilson;J Clin Oncol.,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory Presentation of a Primary Extranodal Diffuse Large B-cell Lymphoma of the Maxillary Sinus;Cureus;2023-04-23

2. A case report of sinusoidal diffuse large B-cell lymphoma in a STK4 deficient patient;Medicine;2020-02

3. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis;Annals of Hematology;2018-04-04

4. CD5 and CD43 expression are associate with poor prognosis in DLBCL patients;Open Medicine;2018-01-01

5. A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib;Case Reports in Hematology;2018